CytRx Corp. (CYTR), a biopharmaceutical research and development company, specializes in developing treatments for various forms of cancer. In addition to advancing its existing oncology candidates through clinical trials, the company is expanding its pipeline based on a novel linker platform technology that can be utilized with multiple chemotherapeutic agents and could allow for greater concentration of drug at tumor sites.